JP2024515879A - 抗ｓｉｇｌｅｃ組成物及びその使用 - Google Patents

抗ｓｉｇｌｅｃ組成物及びその使用 Download PDF

Info

Publication number
JP2024515879A
JP2024515879A JP2023566870A JP2023566870A JP2024515879A JP 2024515879 A JP2024515879 A JP 2024515879A JP 2023566870 A JP2023566870 A JP 2023566870A JP 2023566870 A JP2023566870 A JP 2023566870A JP 2024515879 A JP2024515879 A JP 2024515879A
Authority
JP
Japan
Prior art keywords
cancer
siglec
antibody
seq
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515879A5 (enExample
Inventor
リウ、ヤン
チョン、パン
デブンポート、マーティン
リウ、ミンユエ
Original Assignee
オンコシーフォー、インク．
ユニバーシティ オブ メリーランド ボルチモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコシーフォー、インク．, ユニバーシティ オブ メリーランド ボルチモア filed Critical オンコシーフォー、インク．
Publication of JP2024515879A publication Critical patent/JP2024515879A/ja
Publication of JP2024515879A5 publication Critical patent/JP2024515879A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023566870A 2021-04-30 2022-04-29 抗ｓｉｇｌｅｃ組成物及びその使用 Pending JP2024515879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182271P 2021-04-30 2021-04-30
US63/182,271 2021-04-30
PCT/US2022/027006 WO2022232558A1 (en) 2021-04-30 2022-04-29 Anti-siglec compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024515879A true JP2024515879A (ja) 2024-04-10
JP2024515879A5 JP2024515879A5 (enExample) 2025-03-17

Family

ID=83848703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566870A Pending JP2024515879A (ja) 2021-04-30 2022-04-29 抗ｓｉｇｌｅｃ組成物及びその使用

Country Status (10)

Country Link
US (1) US20240218067A1 (enExample)
EP (1) EP4329806A4 (enExample)
JP (1) JP2024515879A (enExample)
KR (1) KR20240006519A (enExample)
CN (1) CN117355331A (enExample)
AU (1) AU2022267362A1 (enExample)
CA (1) CA3216324A1 (enExample)
IL (1) IL308137A (enExample)
MX (1) MX2023012759A (enExample)
WO (1) WO2022232558A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643575B (zh) * 2023-11-03 2026-04-24 中山大学 一种纳米材料及其制备方法和应用
WO2026055671A1 (en) * 2024-09-09 2026-03-12 OncoC4, Inc. Anti-siglec compositions and uses thereof for treating neurodegenerative diseases
CN120459278A (zh) * 2025-07-14 2025-08-12 南京医科大学 Siglec-10/G或包含Siglec-10/G蛋白结构的融合蛋白在制备治疗胶质瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171114A1 (en) * 2008-04-11 2012-07-05 Haeuw Jean-Francois Anti-cd151 antibodies and their use in the treatment of cancer
US20120201819A1 (en) * 2009-03-04 2012-08-09 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the cd-24-hmgb1-siglec10 axis
US20180344829A1 (en) * 2015-11-17 2018-12-06 Innate Pharma Siglec-10 antibodies
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107171A1 (en) * 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171114A1 (en) * 2008-04-11 2012-07-05 Haeuw Jean-Francois Anti-cd151 antibodies and their use in the treatment of cancer
US20120201819A1 (en) * 2009-03-04 2012-08-09 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the cd-24-hmgb1-siglec10 axis
US20180344829A1 (en) * 2015-11-17 2018-12-06 Innate Pharma Siglec-10 antibodies
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer

Also Published As

Publication number Publication date
AU2022267362A1 (en) 2023-11-09
IL308137A (en) 2023-12-01
EP4329806A1 (en) 2024-03-06
MX2023012759A (es) 2023-11-13
WO2022232558A1 (en) 2022-11-03
CA3216324A1 (en) 2022-11-03
US20240218067A1 (en) 2024-07-04
EP4329806A4 (en) 2025-09-17
TW202305005A (zh) 2023-02-01
AU2022267362A9 (en) 2023-11-16
CN117355331A (zh) 2024-01-05
KR20240006519A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
KR102584675B1 (ko) GUCY2c에 특이적인 항체 및 이의 용도
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
EP3936526A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2020098734A1 (zh) 抗tigit抗体及其用途
JP2021526509A (ja) 抗ｃｄ２４組成物及びその使用
JP2021524251A (ja) Ｃｄ３に特異的な抗体及びその使用
JP2022525071A (ja) Ｃｔｌａ－４遮断剤とｐｄ－１遮断剤とを含む抗癌併用療法
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
US20240218067A1 (en) Anti-siglec compositions and uses thereof
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
AU2021311701A1 (en) Anti-CTLA-4 antibody and use thereof
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
JP2026026083A (ja) がんの治療のための多重特異性抗体
WO2020058762A1 (en) Antibodies specific to ctla-4 and uses thereof
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
EA049996B1 (ru) Антитело к siglec-10 (варианты)
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
HK40115416A (en) Combination of multi-specific molecule and immune checkpoint inhibitor
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724